Mary-Keara Boss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mary-Keara Boss has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Daniel P. Regan
Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA
9 shared publications - Mark W. Dewhirst
Department of Radiation Oncology, Duke University School of Medicine, Durham, NC 27710, USA
9 shared publications - Steven Dow
Department of Clinical Sciences, Colorado State University, Fort Collins, CO 80523, USA
9 shared publications - Tiffany Wormhoudt Martin
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences Colorado State University Fort Collins Colorado USA
8 shared publications - Alexander J. Hish
Northwestern Memorial Hospital, Chicago, USA
7 shared publications - Alexander Leandros Lazarides
Department of Sarcoma, Moffitt Cancer Center, 12920 USF Magnolia Drive, Tampa, FL 33612, USA
7 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 67 (4) , e70212
Clinically Relevant Motion of Canine Thoracic Tumors Is Seen Between Inspiratory and Expiratory Breath Holds on Computed Tomography Performed for Radiation Treatment Planning
Advancements in radiation therapy allow for targeting smaller tumor volumes with exceedingly conformal precision. Target motion during the breathing cycle needs to be anticipated. To date, no information exists that characterizes the motion of canine thoracic tumors during the respiratory cycle. The primary purpose of this study is to assess the pattern of motion of thoracic tumors in three‐dimensional (3D) space between inspiratory and expiratory breath holds as a surrogate measurement of the breathing cycle. A secondary aim is to evaluate whether tumor position within the thorax relates to the degree of motion. Fourteen dogs were prospectively enrolled and received thoracic computed tomography (CT) scans with pre‐ and post‐contrast inspiratory and expiratory phases achieved via manual breath holds. Gross tumor volume (GTV) and normal structures were delineated on inspiratory and expiratory image sets, and shifts were measured and analyzed. Smaller tumors had more motion in the dorsoventral direction compared to larger tumors ( p = 0.047; r s = −0.44). The same observation was appreciated in the craniocaudal direction ( p = 0.008; r s = −0.56). Dogs with multiple tumors had more motion in the dorsoventral direction and the craniocaudal direction compared to dogs with solitary tumors ( p = 0.035; p = 0.022). Caudal tumors had significantly more 3D motion ( p < 0.001) and craniocaudal motion ( p < 0.001) compared to cranial tumors, whereas there was significantly more lateral motion ( p < 0.001) between peripheral and central tumors, but no significant difference in 3D motion ( p = 0.24). The variability of tumor motion between canine patients supports individualized assessments of each case to ensure best practice.
- 14 July 2026
- Published by Wiley in Veterinary Radiology & Ultrasound
- Vol. 67 (4) , e70212
Open AccessClinically Relevant Motion of Canine Thoracic Tumors Is Seen Between Inspiratory and Expiratory Breath Holds on Computed Tomography Performed for Radiation Treatment Planning
Advancements in radiation therapy allow for targeting smaller tumor volumes with exceedingly conformal precision. Target motion during the breathing cycle needs to be anticipated. To date, no information exists that characterizes the motion of canine thoracic tumors during the respiratory cycle. The primary purpose of this study is to assess the pattern of motion of thoracic tumors in three‐dimensional (3D) space between inspiratory and expiratory breath holds as a surrogate measurement of the breathing cycle. A secondary aim is to evaluate whether tumor position within the thorax relates to the degree of motion. Fourteen dogs were prospectively enrolled and received thoracic computed tomography (CT) scans with pre‐ and post‐contrast inspiratory and expiratory phases achieved via manual breath holds. Gross tumor volume (GTV) and normal structures were delineated on inspiratory and expiratory image sets, and shifts were measured and analyzed. Smaller tumors had more motion in the dorsoventral direction compared to larger tumors ( p = 0.047; r s = −0.44). The same observation was appreciated in the craniocaudal direction ( p = 0.008; r s = −0.56). Dogs with multiple tumors had more motion in the dorsoventral direction and the craniocaudal direction compared to dogs with solitary tumors ( p = 0.035; p = 0.022). Caudal tumors had significantly more 3D motion ( p < 0.001) and craniocaudal motion ( p < 0.001) compared to cranial tumors, whereas there was significantly more lateral motion ( p < 0.001) between peripheral and central tumors, but no significant difference in 3D motion ( p = 0.24). The variability of tumor motion between canine patients supports individualized assessments of each case to ensure best practice.
- Open Access
- 19 April 2026
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 24 (3) , 485-498
Retrospective Analysis of Survival and Adverse Effects Associated With Stereotactic Body Radiation Therapy in 12 Dogs With Hepatocellular Carcinoma
This retrospective analysis evaluated 12 dogs with hepatocellular carcinoma (HCC) who received stereotactic body radiation therapy (SBRT). Dogs received between 6 and 25 Grey (Gy) per fraction for 1–5 fractions for a total dose of 13–30 Gy. Eleven patients (92%) experienced acute adverse effects (AE), with the majority being VRTOG grade 2–3 stomach/small intestinal AE. Additionally, 70% of patients experienced late AE, with the majority being VRTOG grade 2 stomach/small intestinal AE. Liver‐specific side effects were also observed following SBRT, including VCOG‐CTCAE grade 4 hepatic encephalopathy and grade 5 liver failure. There was a statistically significant correlation between the gross tumour volume (GTV) and the overall survival time (OST; p = 0.02) as well as a significant correlation between the percentage of normal liver affected by the mass and the severity of acute stomach/small intestinal AE ( p = 0.01). Statistically significant correlations were observed between the dose of radiation to the normal liver, starting with a threshold dose of 7 Gy, and an increase of the liver enzyme ALT. Median survival time (MST) of the cohort was 301 days. Dogs with > 28.7% of the liver affected by the mass had a MST of 182 days vs. 419 days for dogs with < 28.7% affected ( p = 0.009). This study suggests parameters for GTV, percentage of liver affected, and dose to normal liver could affect survival and the likelihood for adverse effects and liver enzyme elevation when treating with SBRT.
- 19 April 2026
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 24 (3) , 485-498
Open AccessRetrospective Analysis of Survival and Adverse Effects Associated With Stereotactic Body Radiation Therapy in 12 Dogs With Hepatocellular Carcinoma
This retrospective analysis evaluated 12 dogs with hepatocellular carcinoma (HCC) who received stereotactic body radiation therapy (SBRT). Dogs received between 6 and 25 Grey (Gy) per fraction for 1–5 fractions for a total dose of 13–30 Gy. Eleven patients (92%) experienced acute adverse effects (AE), with the majority being VRTOG grade 2–3 stomach/small intestinal AE. Additionally, 70% of patients experienced late AE, with the majority being VRTOG grade 2 stomach/small intestinal AE. Liver‐specific side effects were also observed following SBRT, including VCOG‐CTCAE grade 4 hepatic encephalopathy and grade 5 liver failure. There was a statistically significant correlation between the gross tumour volume (GTV) and the overall survival time (OST; p = 0.02) as well as a significant correlation between the percentage of normal liver affected by the mass and the severity of acute stomach/small intestinal AE ( p = 0.01). Statistically significant correlations were observed between the dose of radiation to the normal liver, starting with a threshold dose of 7 Gy, and an increase of the liver enzyme ALT. Median survival time (MST) of the cohort was 301 days. Dogs with > 28.7% of the liver affected by the mass had a MST of 182 days vs. 419 days for dogs with < 28.7% affected ( p = 0.009). This study suggests parameters for GTV, percentage of liver affected, and dose to normal liver could affect survival and the likelihood for adverse effects and liver enzyme elevation when treating with SBRT.
- Open Access
- 5 August 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (8) , 735
The Effect of Cannabidiol in Conjunction with Radiation Therapy on Canine Glioma Cell Line Transplanted in Immunodeficient Mice
Glioma is a type of neoplasia that spontaneously arises from the glial cells of the brain in humans and dogs, and its prognosis is grave. Current treatment options for glioma include surgery, radiation therapy, chemotherapy, or symptomatic treatment. Evidence has shown that cannabidiol (CBD) may have anticancer, anti-angiogenic, and anti-inflammatory properties in both in vitro and in vivo studies. In this in vivo murine experiment, the canine glioma cell line J3TBG was injected into the frontoparietal cortex of immunodeficient mice using xenogeneic tissue transplantation. A total of 20 mice were randomly assigned to one of four treatment groups—Control group (C), CBD group (CBD), Radiation Therapy group (RT), and CBD plus Radiation Therapy group (CBD + RT). After transplantation of J3TBG, a single fraction of 5.5 Gy RT was administered to the RT and CBD + RT groups, and CBD was administered daily to the CBD and CBD + RT groups. Necropsies were performed to collect blood and brain tissue. Although there was not a statistically significant difference, the survival time among mice were longer in the CBD + RT group than the RT group. These results indicate that CBD may be used as an adjunctive therapy to enhance RT treatment. Larger cohort studies are required to substantiate the hypothesis.
- 5 August 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (8) , 735
Open AccessThe Effect of Cannabidiol in Conjunction with Radiation Therapy on Canine Glioma Cell Line Transplanted in Immunodeficient Mice
Glioma is a type of neoplasia that spontaneously arises from the glial cells of the brain in humans and dogs, and its prognosis is grave. Current treatment options for glioma include surgery, radiation therapy, chemotherapy, or symptomatic treatment. Evidence has shown that cannabidiol (CBD) may have anticancer, anti-angiogenic, and anti-inflammatory properties in both in vitro and in vivo studies. In this in vivo murine experiment, the canine glioma cell line J3TBG was injected into the frontoparietal cortex of immunodeficient mice using xenogeneic tissue transplantation. A total of 20 mice were randomly assigned to one of four treatment groups—Control group (C), CBD group (CBD), Radiation Therapy group (RT), and CBD plus Radiation Therapy group (CBD + RT). After transplantation of J3TBG, a single fraction of 5.5 Gy RT was administered to the RT and CBD + RT groups, and CBD was administered daily to the CBD and CBD + RT groups. Necropsies were performed to collect blood and brain tissue. Although there was not a statistically significant difference, the survival time among mice were longer in the CBD + RT group than the RT group. These results indicate that CBD may be used as an adjunctive therapy to enhance RT treatment. Larger cohort studies are required to substantiate the hypothesis.
- Open Access
- 17 July 2025
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 23 (4) , 518-527
Evaluating the Impact of Elective Nodal Irradiation for Dogs With Oral Malignant Melanoma Undergoing Hypofractionated Radiotherapy
Hypofractionated radiotherapy (hRT) is often used to treat dogs with oral malignant melanoma (OMM); however, there is no consensus as to whether clinically uninvolved regional lymph nodes should be prophylactically irradiated. The objective of this retrospective study is to compare outcomes for dogs with OMM treated with hRT+/– elective nodal irradiation (ENI). Dogs with nonmetastatic OMM undergoing hRT+/– ENI with a prescription of ≥ 30 Gy were included. Survival statistics were evaluated with Kaplan–Meier curves and log‐rank testing. Univariable and multivariable Cox proportional hazard models were used to assess how survival was impacted by the use of ENI, WHO T‐stage, mitotic count, RT technique, and use of Oncept melanoma vaccine. Data from four institutions and 100 dogs (80 with ENI and 20 without) were included. In the ENI group, nodal and distant metastases were documented in 4 and 30 dogs, respectively. In the non‐ENI group, nodal and distant metastases were documented in 6 and 4 dogs, respectively. There was no significant difference in the 1‐year nodal or distant progression‐free intervals ( p = 0.174, and 0.563, respectively). The only variable maintaining significance on multivariable analysis was T‐stage (overall progression‐free survival, HR 1.393, p = 0.006; overall survival time, HR 1.426, p = 0.005; distant progression‐free interval, HR 1.521, p = 0.033). ENI did not measurably alter the oncologic outcomes in this study population. Results should be interpreted cautiously given the lack of standardised staging/restaging and the heterogenous nature of this clinical population. Future investigations are needed to clarify the role of ENI in the treatment of canine OMM.
- 17 July 2025
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 23 (4) , 518-527
Open AccessEvaluating the Impact of Elective Nodal Irradiation for Dogs With Oral Malignant Melanoma Undergoing Hypofractionated Radiotherapy
Hypofractionated radiotherapy (hRT) is often used to treat dogs with oral malignant melanoma (OMM); however, there is no consensus as to whether clinically uninvolved regional lymph nodes should be prophylactically irradiated. The objective of this retrospective study is to compare outcomes for dogs with OMM treated with hRT+/– elective nodal irradiation (ENI). Dogs with nonmetastatic OMM undergoing hRT+/– ENI with a prescription of ≥ 30 Gy were included. Survival statistics were evaluated with Kaplan–Meier curves and log‐rank testing. Univariable and multivariable Cox proportional hazard models were used to assess how survival was impacted by the use of ENI, WHO T‐stage, mitotic count, RT technique, and use of Oncept melanoma vaccine. Data from four institutions and 100 dogs (80 with ENI and 20 without) were included. In the ENI group, nodal and distant metastases were documented in 4 and 30 dogs, respectively. In the non‐ENI group, nodal and distant metastases were documented in 6 and 4 dogs, respectively. There was no significant difference in the 1‐year nodal or distant progression‐free intervals ( p = 0.174, and 0.563, respectively). The only variable maintaining significance on multivariable analysis was T‐stage (overall progression‐free survival, HR 1.393, p = 0.006; overall survival time, HR 1.426, p = 0.005; distant progression‐free interval, HR 1.521, p = 0.033). ENI did not measurably alter the oncologic outcomes in this study population. Results should be interpreted cautiously given the lack of standardised staging/restaging and the heterogenous nature of this clinical population. Future investigations are needed to clarify the role of ENI in the treatment of canine OMM.
- 16 June 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (3) , 852-859
Identifying Pathogenic Contributors of Radiodermatitis Ameliorated by Smad7-Based Targeting in Canine and Mouse Models
- 16 June 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (3) , 852-859
Identifying Pathogenic Contributors of Radiodermatitis Ameliorated by Smad7-Based Targeting in Canine and Mouse Models
- 27 December 2024
- Published by MyJove Corporation
- No. 214,p. e67577
JoVE Video Dataset
Evaluating the local immune microenvironment of the canine nasal cavity can be important for investigating normal tissue health and disease conditions, particularly those associated with local inflammation. We have optimized a technique to evaluate the local nasal immune microenvironment of dogs via serial nasal lavage. Briefly, with dogs under anesthesia and positioned in sternal recumbency, prewarmed sterile saline is flushed into the affected nostril using a flexible soft rubber catheter. The fluid backflow is collected into conical tubes, and this process is repeated. The fluids containing dislodged cells and proteins are pooled, and the pooled nasal lavage samples are filtered through a cell strainer to remove large debris and mucus. Samples are centrifuged and the cell pellets are isolated for analysis. Once the samples have been processed, analyses that may follow nasal lavage include flow cytometry, transcriptomic analysis of cells via bulk or single-cell RNA seq, and/or quantification of cytokines present in the lavage fluid.
- 27 December 2024
- Published by MyJove Corporation
- No. 214,p. e67577
JoVE Video Dataset
Evaluating the local immune microenvironment of the canine nasal cavity can be important for investigating normal tissue health and disease conditions, particularly those associated with local inflammation. We have optimized a technique to evaluate the local nasal immune microenvironment of dogs via serial nasal lavage. Briefly, with dogs under anesthesia and positioned in sternal recumbency, prewarmed sterile saline is flushed into the affected nostril using a flexible soft rubber catheter. The fluid backflow is collected into conical tubes, and this process is repeated. The fluids containing dislodged cells and proteins are pooled, and the pooled nasal lavage samples are filtered through a cell strainer to remove large debris and mucus. Samples are centrifuged and the cell pellets are isolated for analysis. Once the samples have been processed, analyses that may follow nasal lavage include flow cytometry, transcriptomic analysis of cells via bulk or single-cell RNA seq, and/or quantification of cytokines present in the lavage fluid.
- 27 December 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 214,p. e67577
Saline Lavage for Sampling of the Canine Nasal Immune Microenvironment
Evaluating the local immune microenvironment of the canine nasal cavity can be important for investigating normal tissue health and disease conditions, particularly those associated with local inflammation. We have optimized a technique to evaluate the local nasal immune microenvironment of dogs via serial nasal lavage. Briefly, with dogs under anesthesia and positioned in sternal recumbency, prewarmed sterile saline is flushed into the affected nostril using a flexible soft rubber catheter. The fluid backflow is collected into conical tubes, and this process is repeated. The fluids containing dislodged cells and proteins are pooled, and the pooled nasal lavage samples are filtered through a cell strainer to remove large debris and mucus. Samples are centrifuged and the cell pellets are isolated for analysis. Once the samples have been processed, analyses that may follow nasal lavage include flow cytometry, transcriptomic analysis of cells via bulk or single-cell RNA seq, and/or quantification of cytokines present in the lavage fluid.
- 27 December 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 214,p. e67577
Saline Lavage for Sampling of the Canine Nasal Immune Microenvironment
Evaluating the local immune microenvironment of the canine nasal cavity can be important for investigating normal tissue health and disease conditions, particularly those associated with local inflammation. We have optimized a technique to evaluate the local nasal immune microenvironment of dogs via serial nasal lavage. Briefly, with dogs under anesthesia and positioned in sternal recumbency, prewarmed sterile saline is flushed into the affected nostril using a flexible soft rubber catheter. The fluid backflow is collected into conical tubes, and this process is repeated. The fluids containing dislodged cells and proteins are pooled, and the pooled nasal lavage samples are filtered through a cell strainer to remove large debris and mucus. Samples are centrifuged and the cell pellets are isolated for analysis. Once the samples have been processed, analyses that may follow nasal lavage include flow cytometry, transcriptomic analysis of cells via bulk or single-cell RNA seq, and/or quantification of cytokines present in the lavage fluid.
- 31 October 2024
- Published by Radiation Research Society in Radiation Research
- Vol. 202 (6) , 807-824
Response of Spontaneous Oral Tumors in Canine Cancer Patients Treated with Stereotactic Body Radiation Therapy (SBRT)
The objective of this study is describe outcome and toxicity for dogs with oral tumors, specifically oral malignant melanoma (OMM), squamous cell carcinoma (SCC), and soft tissue sarcoma (STS) after stereotactic body radiation therapy (SBRT). A single institution retrospective study was conducted. Outcomes were analyzed using Kaplan-Meier analysis and Cox proportional hazard analysis. Treatment responses at different time points were evaluated with Pearson's Chi-squared test to identify prognostic factors. Acute and late toxicities were recorded according to VRTOG criteria and were analyzed to identify risk factors. Adverse events other than acute and late toxicities were recorded. A total of 98 patients met the inclusion criteria (OMM n = 37; SCC n = 18; STS n = 43). The SBRT prescription was 1–6 fractions, with a total dose range of 12–40 Gy. Local progression-free survival (PFS) for OMM, SCC, and STS was 187, 253, and 161 days, respectively. Overall PFS was 152 days and median survival time (MST) was 270 days, with no statistical difference between tumor types. The presence of lymph node metastasis and the use of elective nodal irradiation (ENI) were associated with shorted PFS and MST. Severe acute toxicities to organs at risk affected 10/85 (11.8%) of patients. Osteoradionecrosis and oronasal fistula formation occurred in 23/81 (28.4%) of patients and was significantly associated with tumor type (SCC, P = 0.006). SBRT can be offered as a treatment option for oral tumors in dogs. Toxicities were common and warrant risk factor considerations and adjustments to current SBRT protocols.
- 31 October 2024
- Published by Radiation Research Society in Radiation Research
- Vol. 202 (6) , 807-824
Response of Spontaneous Oral Tumors in Canine Cancer Patients Treated with Stereotactic Body Radiation Therapy (SBRT)
The objective of this study is describe outcome and toxicity for dogs with oral tumors, specifically oral malignant melanoma (OMM), squamous cell carcinoma (SCC), and soft tissue sarcoma (STS) after stereotactic body radiation therapy (SBRT). A single institution retrospective study was conducted. Outcomes were analyzed using Kaplan-Meier analysis and Cox proportional hazard analysis. Treatment responses at different time points were evaluated with Pearson's Chi-squared test to identify prognostic factors. Acute and late toxicities were recorded according to VRTOG criteria and were analyzed to identify risk factors. Adverse events other than acute and late toxicities were recorded. A total of 98 patients met the inclusion criteria (OMM n = 37; SCC n = 18; STS n = 43). The SBRT prescription was 1–6 fractions, with a total dose range of 12–40 Gy. Local progression-free survival (PFS) for OMM, SCC, and STS was 187, 253, and 161 days, respectively. Overall PFS was 152 days and median survival time (MST) was 270 days, with no statistical difference between tumor types. The presence of lymph node metastasis and the use of elective nodal irradiation (ENI) were associated with shorted PFS and MST. Severe acute toxicities to organs at risk affected 10/85 (11.8%) of patients. Osteoradionecrosis and oronasal fistula formation occurred in 23/81 (28.4%) of patients and was significantly associated with tumor type (SCC, P = 0.006). SBRT can be offered as a treatment option for oral tumors in dogs. Toxicities were common and warrant risk factor considerations and adjustments to current SBRT protocols.
- Open Access
- 2 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1838
Investigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model
Tyrosine kinase inhibitors (TKIs) may be combined with radiation therapy (RT) to enhance tumor control; however, increased incidences of gastrointestinal (GI) toxicity have been reported with this combination. We hypothesize that toxicity is due to compromised intestinal healing caused by inhibition of vascular repair and proliferation pathways. This study explores underlying tissue toxicity associated with abdominal RT and concurrent sunitinib in a mouse model. Four groups of CD-1 mice were treated with 12 Gy abdominal RT, oral sunitinib, abdominal RT + sunitinib, or sham treatment. Mice received oral sunitinib or the vehicle via gavage for 14 days. On day 7, mice were irradiated with 12 Gy abdominal RT or sham treated. Mice were euthanized on day 14 and intestinal tract was harvested for semiquantitative histopathologic evaluation and immunohistochemical quantification of proliferation (Ki67) and vascular density (CD31). Non-irradiated groups had stable weights while abdominal irradiation resulted in weight loss, with mice receiving RT + SUN having greater weight loss than mice receiving RT alone. Semiquantitative analysis showed significant increases in inflammation in irradiated groups. The difference in the density of CD31+ cells was significantly increased in RT alone compared to SUN alone. Ki67+ density was not significant. In summary, we identify a lack of angiogenic response in irradiated GI tissues when abdominal RT is combined with a TKI, which may correlate with clinical toxicities seen in canine and human patients receiving combined treatment.
- 2 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (3) , 1838
Open AccessInvestigation of Gastrointestinal Toxicities Associated with Concurrent Abdominal Radiation Therapy and the Tyrosine Kinase Inhibitor Sunitinib in a Mouse Model
Tyrosine kinase inhibitors (TKIs) may be combined with radiation therapy (RT) to enhance tumor control; however, increased incidences of gastrointestinal (GI) toxicity have been reported with this combination. We hypothesize that toxicity is due to compromised intestinal healing caused by inhibition of vascular repair and proliferation pathways. This study explores underlying tissue toxicity associated with abdominal RT and concurrent sunitinib in a mouse model. Four groups of CD-1 mice were treated with 12 Gy abdominal RT, oral sunitinib, abdominal RT + sunitinib, or sham treatment. Mice received oral sunitinib or the vehicle via gavage for 14 days. On day 7, mice were irradiated with 12 Gy abdominal RT or sham treated. Mice were euthanized on day 14 and intestinal tract was harvested for semiquantitative histopathologic evaluation and immunohistochemical quantification of proliferation (Ki67) and vascular density (CD31). Non-irradiated groups had stable weights while abdominal irradiation resulted in weight loss, with mice receiving RT + SUN having greater weight loss than mice receiving RT alone. Semiquantitative analysis showed significant increases in inflammation in irradiated groups. The difference in the density of CD31+ cells was significantly increased in RT alone compared to SUN alone. Ki67+ density was not significant. In summary, we identify a lack of angiogenic response in irradiated GI tissues when abdominal RT is combined with a TKI, which may correlate with clinical toxicities seen in canine and human patients receiving combined treatment.